Tipranavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and is a rare cause of clinically apparent, acute liver injury. In coinfected patients, hepatic injury during highly active antiretroviral therapy including tipranavir may be a result of exacerbation of the underlying chronic hepatitis B or C, rather than a direct effect of the medication.
Tipranavir (tye pran' a vir) a nonpeptidic antiretroviral protease inhibitor that acts by binding to the catalytic site of the HIV protease, thereby preventing the cleavage of viral polyprotein precursors into mature, functional proteins that are necessary for viral replication.
Tipranavir was approved for use in the United States in adults in 2005 and for children in 2008 for the therapy of HIV infection in combination with other antiretroviral agents. Tipranavir is typically used in combination with low “booster” doses of ritonavir, which inhibits its hepatic metabolism and improves its pharmacokinetics. Tipranavir is available in capsules of 250 mg and as an oral solution (100 mg/mL) for pediatric use under the brand name Aptivus.
The recommended dosage of tipranavir for adults is 500 mg in combination with ritonavir 200 mg, both taken twice daily. The dose in children is based upon body weight or body surface area.
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Nucleoside Analogues (HIV)
- Protease Inhibitors (HIV)
HCV NS5A Inhibitors
HCV NS5B (Polymerase) Inhibitors
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Drugs for Herpes Virus Infections (HSV, CMV, others)
Drugs for Influenza